2018 Investor Presentation

Lantheus to Present at the Wells Fargo Healthcare Conference
BEDFORD, Mass. , Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today
August 31, 2023
Lantheus Reports Second Quarter 2023 Financial Results
Worldwide revenue of $321.7 million for the second quarter 2023, representing an increase of 43.8% from the prior year period GAAP net income of $94.1 million for the second quarter 2023, compared to GAAP net income of $43.1 million in the prior year period GAAP fully diluted net income per share
August 3, 2023
Lantheus to Present at the Jefferies Healthcare Conference
BEDFORD, Mass. , June 01, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today
June 1, 2023
Lantheus Reports First Quarter 2023 Financial Results
Worldwide revenue of $300.8 million for the first quarter 2023, representing an increase of 44.0% from the prior year period GAAP net loss of $2.8 million for the first quarter 2023, compared to GAAP net income of $43.0 million in the prior year period GAAP fully diluted net loss per share of $.04
May 4, 2023
Lantheus Announces Two Key Executive Promotions
Paul Blanchfield promoted to President; Dan Niedzwiecki promoted to Chief Administrative Officer BEDFORD, Mass. , March 17, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and
March 17, 2023
Lantheus Reports Fourth Quarter and Full Year 2022 Financial Results
Worldwide revenue of $263.2 million and $935.1 million for the fourth quarter and full year 2022, representing increases of 103.1% and 119.9% over the prior year periods, respectively GAAP net loss of $119.2 million and GAAP net income of $28.1 million for the fourth quarter and full year 2022,
February 23, 2023
Lantheus to Present at the J.P. Morgan 2023 Healthcare Conference
NORTH BILLERICA, Mass. , Jan. 04, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc.  (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow
January 4, 2023